Skip to content
BioAlmanacPeptide reference
Menu

Comparison

Tirzepatide vs survodutide

Two dual agonists that picked different second receptors, GIP in one case and glucagon in the other, and that sit at very different stages of evidence.

Both act on GLP-1 plus one more receptor, and which one they add is the entire difference. Tirzepatide adds GIP. Survodutide adds glucagon.

Glucagon is the route with less precedent among approved drugs, and it is the same one retatrutide adds on top of tirzepatide's pair. What glucagon agonism does over years is the open question behind both of them.

They are also not at the same stage. Tirzepatide has completed phase 3 and holds approvals; survodutide is further back.

Tirzepatide vs survodutide compared row by row
AttributeTirzepatideSurvodutide
Receptor targetsGLP-1, GIPGLP-1, glucagon
Evidence levelApprovedClinical
Dosing frequencyOnce weeklyOnce weekly
Reported weight reductionAround 21% at the highest doseAround 19% in phase 2
AvailabilityApproved and prescribedNot approved

Things worth knowing

  • A phase 2 figure and a phase 3 figure are different kinds of number, and effect sizes commonly shrink between them.
  • Glucagon agonism raises energy expenditure as well as suppressing appetite. That is the argument for it. It is also the arm with the least long-term human data behind it anywhere in this class.

Full profile

Tirzepatide

A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.

Full profile

Survodutide

A GLP-1 and glucagon dual agonist in phase 3, and one of the more advanced candidates for fatty liver disease rather than weight alone.

Related

Another comparisonSemaglutide vs tirzepatideBoth are once-weekly incretin agonists approved for weight management. The difference is how many receptors each one acts on, and what that does to the dosing scale.Another comparisonTirzepatide vs retatrutideTwo and three receptors respectively. Retatrutide reported the larger weight reduction; tirzepatide has a completed phase 3 programme and an approval. This is a different kind of claim.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice.

Next

Where to take this